News | July 28, 2021
Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The appointment is effective from May 01, 2023 for five years
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
Subscribe To Our Newsletter & Stay Updated
